EUVIMEDEUVIMED entdecken
Crossref

Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs/NF-κB signaling pathway

Yifan Zhang, Jiarou Wang, Shuo Yang, Haixin Kou, Ping Liu

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yifan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Abietanes, Atherosclerosis, Fatty Liver. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Tanshinone IIA (Tan IIA) exhibits therapeutic potential for atherosclerosis (AS) and hepatic steatosis (HS). The study aims to explore the mechanisms underlying the anti-atherosclerosis and anti-hepatic steatosis effects of Tan IIA. METHODS: The LDLR-/-mice were divided into control, model, low/high Tan IIA and atorvastatin group, which fed with High-fat diet to build NAFLD-associated AS model, then administrated with 0.9 % saline, Tan IIA or atorvastatin. RAW264.7 cells divided into control, LPS, LPS plus low/high Tan IIA and LPS plus Tan IIA plus JNK activator group. The different goups' pathological changes visualized with H&E, Oil Red O and Immunofluorescence staining. The therapeutic effect of Tan IIA was reflected by lipids metabolism changes, hepatic indexes, inflammation levels. ELISA, RT-qPCR and Western blot assay were used to determine the inflammatory factors and upstream proteins. Molecular docking was used to reconfirm the importance of genes studied and locate the specific gene will study. RESULTS: Tan IIA alleviated LDLR-/-mice AS and HS by reducing AS plaque area, lowering serum &liver lipid levels (TC, TG), improving liver function (AST, ALT). Tan IIA decreased serum inflammation levels (IL-1β, IL-6, TNF-α) and aorta & liver inflammatory-related cytokines levels (iNOS, VCAM-1, IL-6) and inhibited the phosphorylation of aorta & liver protein ERK1/2, JNK, p38 and NF-κB p65, which were validated in the LPS-stimulated macrophages supernatant and cells. CONCLUSIONS: The study indicated that Tan IIA can alleviate atherosclerosis and hepatic steatosis via down-regulating MAPKs/NF-κB signaling pathway. This provides a potential therapeutic strategy for the co-existing situation of atherosclerosis and hepatic steatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbietanesAtherosclerosisFatty LiverAnimalsMiceRAW 264.7 CellsNF-kappa BMice, KnockoutMaleDown-RegulationLiverSignal TransductionReceptors, LDLDiet, High-FatMice, Inbred C57BLMAP Kinase Signaling SystemDisease Models, Animal

Stichwörter der Autor:innen

AtherosclerosisHepatic steatosisInflammationMAPKs/NF-κBTanshinone IIA

Substanzen

AbietanestanshinoneNF-kappa BReceptors, LDL

Autor:innen und Institutionen

  • Department of Cardiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Cardiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: liuping0207@126.com.

Zitieren

APA

Zhang, Y., Wang, J., Yang, S., Kou, H., & Liu, P. (2025). Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs/NF-κB signaling pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114465

Vancouver

Zhang Y, Wang J, Yang S, Kou H, Liu P. Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs/NF-κB signaling pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114465

BibTeX
@article{Zhang2025,
  author = {Zhang, Yifan and Wang, Jiarou and Yang, Shuo and Kou, Haixin and Liu, Ping},
  title = {Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs/NF-κB signaling pathway},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114465}
}
Kostenlos starten →